Abstract: Objective To evaluate the longterm oncologic and reproductive outcomes of fertilitypreservation therapy for young women with stage I endometrial carcinoma（EC） who wanted to preserve fertility. Methods The oncologic and reproductive outcomes of 16 young patients with stage I endometrial cancer treated with fertilitypreservation therapy from 2005 to 2011 in Nan Fang hospital was retrospectively analyzed. The patients with positive progesterone receptor （PR） were given megestrolacetate （MA） orally at 160mg／day. Excluding the progress of the disease， patients with poor effect were additionally given tamoxifen（TAM） orally at 30mg／day or GnRHα. Patients with negetive PR were additionally given toremifene（TRM） at 60mg／day. Results In this research， 11 of 16 patients showed a response （69％），recurrence time was 8 months （range 5-14）. After a median follow-up time of 58 months （range 24-108）， all patients were survival， 1 patient experienced progression of disease. Three patients succeeded in pregnancy， and 2 born babies. Conclusion Fertilitypreservation therapy for young women with stage I endometrial carcinoma was safe and highly effective. However， definitive admission and close surveillance need more attention.